Coronavirus Disease 2019 Case Series in China: Sequelae and Effectiveness of Vaccination and Antiviral Drugs

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2025 Mar 3

PMID 40027918

Authors

Min Ren

Affiliations

Soon will be listed here.

Abstract

Purpose Of The Study: This study investigated post-coronavirus disease 2019 (COVID-19) sequelae among a sample of the Chinese population, and determined the statistical significance of correlations between age, sex, number of COVID-19 vaccinations, number of SARS-CoV-2 infections, development of pneumonia, use of specific drugs (namatevir/ritonavir, azvudine, molnupiravir), chronic underlying diseases, and post-COVID-19 sequelae.

Methods: Data from 869 patients, who visited the Emergency Department of Beijing Shijitan Hospital (Beijing, China) between December 7, 2022 to January 31, 2024, were collected. The criteria for admission: Age ≥ 14 years old, and diagnosed with ≥ 1 positive result on nucleic acid or antigen tests. Retrospectively analyzed the main manifestations of sequelae, statistical analysis of the relationship between age; sex; underlying diseases; number of COVID-19 vaccinations received; use of specific antiviral drugs for COVID-19 and prognosis, and statistical analyses, including logistic regression, were performed. Differences with P < 0.05 were considered to be statistically significant. Before entering the model, variables are screened using stepwise regression to ensure that the selected variables are the main ones related to the research question, thereby controlling for confounding factors. SPSS version 27 (IBM Corp. Armonk, NY, USA) was used for statistical analysis. In this study, the duration of sequelae ranged from 2 to 13 months.

Results And Conclusions: This study retrospectively analyzed 869 patients (415 male, 454 female), with an average age of 61.52 ± 23.09 years. There were 401 patients without underlying conditions and 468 patients with one or more underlying conditions. Regarding COVID-19 vaccination status, 320 patients were unvaccinated, while 576 patients received at least one dose of the COVID-19 vaccine. Additionally, 514 patients received antiviral medication, while 355 did not receive antiviral treatment. The primary manifestations of post-COVID-19 included shortness of breath, dizziness and weakness, chronic pneumonia, asthma, and reduced sense of smell. Individuals ≥ 70 years of age were more prone to COVID-19 pneumonia. Patients with underlying disease(s) exhibited statistically higher mortality rates after diagnosis of COVID-19. Vaccination against COVID-19 and the use of specific drugs had a statistically significant effect on mortality and the occurrence of post-COVID-19 sequelae. There was no statistically significant difference in COVID-19 infection rates between males and females, although males were more prone to COVID-19 pneumonia. Young women with COVID-19 often experienced no sequelae, and elderly males exhibited a high mortality rate.

References

Davis H, Assaf G, McCorkell L, Wei H, Low R, Reem Y . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38:101019. PMC: 8280690. DOI: 10.1016/j.eclinm.2021.101019. View

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

Tenforde M, Self W, Adams K, Gaglani M, Ginde A, McNeal T . Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021; 326(20):2043-2054. PMC: 8569602. DOI: 10.1001/jama.2021.19499. View

Mancini D, Brunjes D, Lala A, Trivieri M, Contreras J, Natelson B . Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post-Coronavirus Disease. JACC Heart Fail. 2021; 9(12):927-937. PMC: 8629098. DOI: 10.1016/j.jchf.2021.10.002. View

Yan C, Faraji F, Prajapati D, Boone C, DeConde A . Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms. Int Forum Allergy Rhinol. 2020; 10(7):806-813. PMC: 7262089. DOI: 10.1002/alr.22579. View

Paderno A, Schreiber A, Grammatica A, Raffetti E, Tomasoni M, Gualtieri T . Smell and taste alterations in COVID-19: a cross-sectional analysis of different cohorts. Int Forum Allergy Rhinol. 2020; 10(8):955-962. PMC: 7272886. DOI: 10.1002/alr.22610. View

Taquet M, Dercon Q, Harrison P . Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022; 103:154-162. PMC: 9013695. DOI: 10.1016/j.bbi.2022.04.013. View

Willi S, Luthold R, Hunt A, Hanggi N, Sejdiu D, Scaff C . COVID-19 sequelae in adults aged less than 50 years: A systematic review. Travel Med Infect Dis. 2021; 40:101995. PMC: 7898978. DOI: 10.1016/j.tmaid.2021.101995. View

Lechien J, Chiesa-Estomba C, De Siati D, Horoi M, Le Bon S, Rodriguez A . Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020; 277(8):2251-2261. PMC: 7134551. DOI: 10.1007/s00405-020-05965-1. View

10.

Kuodi P, Gorelik Y, Zayyad H, Wertheim O, Beiruti Wiegler K, Abu Jabal K . Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. NPJ Vaccines. 2022; 7(1):101. PMC: 9411827. DOI: 10.1038/s41541-022-00526-5. View

11.

Sato T, Ueha R, Goto T, Yamauchi A, Kondo K, Yamasoba T . Expression of ACE2 and TMPRSS2 Proteins in the Upper and Lower Aerodigestive Tracts of Rats: Implications on COVID 19 Infections. Laryngoscope. 2020; 131(3):E932-E939. DOI: 10.1002/lary.29132. View

12.

Antonelli M, Penfold R, Merino J, Sudre C, Molteni E, Berry S . Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2021; 22(1):43-55. PMC: 8409907. DOI: 10.1016/S1473-3099(21)00460-6. View

13.

Xie Y, Xu E, Bowe B, Al-Aly Z . Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022; 28(3):583-590. PMC: 8938267. DOI: 10.1038/s41591-022-01689-3. View

14.

So M, Kabata H, Fukunaga K, Takagi H, Kuno T . Radiological and functional lung sequelae of COVID-19: a systematic review and meta-analysis. BMC Pulm Med. 2021; 21(1):97. PMC: 7983097. DOI: 10.1186/s12890-021-01463-0. View

15.

Xie Y, Al-Aly Z . Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022; 10(5):311-321. PMC: 8937253. DOI: 10.1016/S2213-8587(22)00044-4. View

16.

Mo X, Jian W, Su Z, Chen M, Peng H, Peng P . Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. 2020; 55(6). PMC: 7236826. DOI: 10.1183/13993003.01217-2020. View